MedTrace Logo

Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy

NCT03986268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-02-22

No results posted yet for this study

Summary

The aim of the study is to evaluate the relationship between the vitamin D replacement and pathological response in patients undergoing neoadjuvant therapy according to different molecular sub types. Because of no study evaluating pathological response to neoadjuvant therapy with vitamin D replacement in patients with breast cancer.

Conditions

  • Vitamin D Deficiency
  • Chemotherapy Effect
  • Pathology

Interventions

DRUG

Vit D

The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.

Sponsors & Collaborators

  • Florence Nightingale Hospital, Istanbul

    lead OTHER

Principal Investigators

  • Çetin Ordu, Assoc. Prof · Gayrettepe FN Hospital

  • Fatma Aktepe, Prof · Gayrettepe FN Hospital

  • Vahit Özmen, Prof · İstanbul FN hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-10
Primary Completion
2020-12-10
Completion
2020-12-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986268 on ClinicalTrials.gov